SCHEMBL6607398

SCHEMBL6607398

O=C(O)CC(NC(=O)Cc1cccc2ccccc12)C(=O)CF

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 2/20 0.56
TDP1 Q9NUW8 1/20 0.52
PIN1 Q13526 1/20 0.50
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
CASP3 P42574 4/20 0.47
LMNA P02545 3/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
RECQL P46063 1/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
PTGER4 P35408 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ITGB3 P05106 1/20 0.47
ITGA2B P08514 1/20 0.47
CASP6 P55212 2/20 0.46
CASP8 Q14790 2/20 0.46
ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6832898 0.88 CASP3 (0.61) CASP1CASP3CASP6CASP8
SCHEMBL6832897 0.88 CASP3 (0.61) CASP1CASP3CASP6CASP8
SCHEMBL1514490 0.87 TDP1 (0.58) CASP1TDP1PIN1MEN1KMT2A
SCHEMBL4954937 0.87 TDP1 (0.58) CASP1TDP1PIN1MEN1KMT2A
SCHEMBL6607128 0.80 CASP3 (0.53) CASP1CASP3HPGDSMN1; SMN2
SCHEMBL7209157 0.79 ANPEP (0.48) CASP1CASP3CASP6CASP8
SCHEMBL8354540 0.79 PSMB8 (0.46) CASP1CASP3CASP6CASP8
SCHEMBL7209163 0.79 ANPEP (0.48) CASP1CASP3CASP6CASP8
SCHEMBL7415071 0.78 CASP1 (0.78) CASP1HPGD
SCHEMBL311929 0.78 NLRP3 (0.54) CASP1TDP1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1163208-B1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMA (US) 2004-05-12 EP disclosed
US-6632962-B2 N-(2-carboxy-1-haloacetylethyl)arylamide derivatives as inhibitors of caspase and cellular apoptosis. VERTEX PHARMACEUTICALS INCORPORATED 2003-10-14 US disclosed
US-20020132833-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2002-09-19 US disclosed
EP-1163208-A4 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMA (US) 2002-07-03 EP disclosed
EP-1163208-A2 CASPASE INHIBITORS AND USES THEREOF Vertex Pharmaceuticals Incorporated (US) 2001-12-19 EP disclosed
WO-2001010383-A2 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2001-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132833-A1 Caspase inhibitors and uses thereof CASP1, CASP3, CASP7 CASP1 1/4885TDP1 223/4885PIN1 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.